Metformin Hydrochloride Rosemont (Metformin Hydrochloride)

Metformin Hydrochloride is a biguanide antidiabetic that acts on glucose metabolism to lower blood sugar levels.

• Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose production and increasing insulin sensitivity.
• Prediabetes (impaired fasting glucose): helps delay progression to overt diabetes through modest glucose‑lowering effects.
• Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity in affected women.

• Metformin Hydrochloride primarily inhibits mitochondrial respiratory‑chain complex I, leading to reduced hepatic gluconeogenesis. It also enhances peripheral glucose uptake by activating AMP‑activated protein kinase (AMPK), which improves insulin sensitivity in muscle and adipose tissue, and modestly decreases intestinal glucose absorption, collectively contributing to lower plasma glucose concentrations.

Metformin Hydrochloride is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite.
• Diarrhea: watery stools occurring especially during treatment initiation.
• Metallic taste: transient alteration in taste perception.
• Flatulence: increased intestinal gas.
• Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

• Lactic acidosis: a rare but potentially fatal accumulation of lactate.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Vitamin B12 deficiency: long‑term use may reduce absorption.
• Hypoglycaemia: when combined with other glucose‑lowering agents.

Metformin Hydrochloride requires careful assessment of patient factors and monitoring to minimise risks.

• Renal function assessment: evaluate eGFR before initiating and periodically thereafter.
• Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment, heart failure, or excessive alcohol intake.
• Alcohol consumption: limit intake as it may increase lactate production.
• Monitoring: regularly check blood glucose, HbA1c, and vitamin B12 levels during long‑term therapy.
• Pregnancy and lactation: use only if clearly needed after consulting a healthcare professional.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, affecting its safety and efficacy.

Major Interactions (Avoid)

• Iodinated contrast media: may precipitate acute renal failure and increase lactic acidosis risk.
• Cimetidine: can raise metformin plasma concentrations.
• Nitrates: combined use may heighten the chance of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• Diuretics: can affect renal function and metformin clearance.
• ACE inhibitors/ARBs: monitor renal function and electrolytes when used together.